Patients Achieved Durable Remission at Weeks 12 and 52¹

Symptom control outcomes in ulcerative colitis. At Week 52 in the COMMAND maintenance study, clinical response rates were 45% with SKYRIZI 180 mg SC, 50% with SKYRIZI 360 mg SC, and 29% with placebo. In the advanced therapy-naive subgroup, rates were 59%, 70%, and 32%, respectively. During the Week 148 open-label extension, clinical response rates were 67% in the overall population and 79% in the advanced therapy-naive subgroup.

Use the lowest effective dosage to maintain therapeutic response.

^{^¶}Advanced therapy-naïve patients include some patients who were exposed to an advanced therapy (biologics, JAK inhibitors, and/or S1P receptor modulators) but did not experience treatment failure.¹

^*Clinical response at Week 4 in UC per partial modified Mayo Score is a composite of Mayo stool frequency and rectal bleeding subscores and was defined as a decrease in total score ≥30% and ≥1 point from baseline and a decrease in rectal bleeding subscore ≥1 or rectal bleeding subscore of 0 or 1.^1,2

^‡Endoscopic improvement in UC is defined as Mayo endoscopic subscore of 0 or 1 without friability.¹ Endoscopic results are based on a full colonoscopy or flexible sigmoidoscopy, at the discretion of the investigator.⁵

^§Endoscopic remission in UC is defined as Mayo endoscopic subscore of 0.¹ Endoscopic results are based on a full colonoscopy or flexible sigmoidoscopy, at the discretion of the investigator.⁵

^||Steroid-free clinical remission in UC is defined as clinical remission per modified Mayo Score (rectal bleeding, stool frequency, endoscopic subscore) at Week 52 and corticosteroid-free for ≥90 days immediately preceding Week 52.

^#Patients who achieved clinical response with SKYRIZI induction therapy and were randomized to receive placebo in the maintenance study.⁵

IV=intravenous; JAK=Janus kinase; OLE=open-label extension; SC=subcutaneous; S1P=sphingosine-1-phosphate.

EARLY SYMPTOM RELIEF

Relief of Rectal Bleeding and Stool Frequency as Early as Week 4^1,2

Clinical Response* at Weeks 4, 8, 12

(Composite of rectal bleeding and stool frequency subscores)

Clinical response rates through Week 12 in the INSPIRE induction study. Response rates increased from Week 0 to 53% at Week 4 and 70% at Week 12 with SKYRIZI 1200 mg IV, compared with 32% at Week 4 and 45% at Week 12 with placebo.

DATA LIMITATION: Clinical response at Weeks 8 and 12 were prespecified, nonranked endpoints not controlled for multiplicity. No conclusions or statistical inferences can be made.

All P-values are SKYRIZI treatment arms vs placebo.

*Clinical response at Week 4 in UC per partial modified Mayo Score is a composite of Mayo stool frequency and rectal bleeding subscores and was defined as a decrease in total score ≥30% and ≥1 point from baseline and a decrease in rectal bleeding subscore ≥1 or rectal bleeding subscore of 0 or 1.^1,2

IV=intravenous.

ENDOSCOPIC CONTROL

Endoscopic Control: Endoscopic Improvement* Seen at Week 52 and up to ~3 Years^2,3,6

Prespecified Subgroup Analysis: In patients who responded to the FDA-approved 1200 mg IV induction dose

ENDOSCOPIC IMPROVEMENT UP TO ~3 YEARS^2,3,6
(Endoscopy subscore of 0 or 1, without friability)

Endoscopic improvement rates in ulcerative colitis. At Week 52 in the COMMAND maintenance study, endoscopic improvement was achieved by 52% of patients receiving SKYRIZI 180 mg SC, 58% receiving SKYRIZI 360 mg SC, and 36% receiving placebo. In the advanced therapy-naive subgroup, rates were 62%, 77%, and 34%, respectively. During the Week 152 open-label extension, endoscopic improvement rates were 75% in the overall population and 83% in the advanced therapy-naive subgroup.

Continuous placebo data not intended for direct comparison.

ALL SUBJECTS MAINTENANCE POPULATION¹

In patients who responded to 1800 mg, 1200 mg or 600 mg in the Phase 2b/3 induction study; 600 mg and 1800 mg are not FDA-approved induction doses.

At Week 52, proportion of patients who achieved ENDOSCOPIC IMPROVEMENT* (secondary endpoint):

51%
SKYRIZI 180 mg SC
(n=179; P<0.001)

48%
SKYRIZI 360 mg SC
(n=186; P<0.001)

31%
Placebo (induction responders)^‡
(n=182)

LIMITATIONS: OLE: All patients completed the 52-week maintenance period and received SKYRIZI 180 mg Q8W regardless of the maintenance dose. An OLE may enrich long-term data as patients intolerant or unresponsive to the drug drop out. Endoscopies at Week 152 were locally read.
AO: A patient may not have had a response at each timepoint and any missing visit data were excluded from calculations for that visit, which may increase the percent responders. All observed data were used regardless of premature discontinuation of study drug or initiation of concomitant medication.³

LIMITATIONS OF PRESPECIFIED SUBGROUP ANALYSIS: Results shown are only among patients who responded to the FDA-approved 1200 mg IV induction dose. Excluded are those who received unapproved induction doses (600 mg or 1800 mg). Data were not controlled for multiplicity. No conclusions or statistical inferences can be made.²

All P-values are SKYRIZI treatment arms vs placebo (induction responders^‡).

^†Advanced therapy-naïve patients include some patients who were exposed to an advanced therapy (biologics, JAK inhibitors, and/or S1P receptor modulators) but did not experience treatment failure.¹

*Endoscopic improvement in UC is defined as Mayo endoscopic subscore of 0 or 1 without friability.¹Endoscopic results are based on a full colonoscopy or flexible sigmoidoscopy, at the discretion of the investigator.⁵

^‡Patients who achieved clinical response with SKYRIZI induction therapy and were randomized to receive placebo in the maintenance study.⁵

^§Patients who responded to placebo in induction were not randomized and continued on placebo in maintenance. These patients were not included in the primary efficacy analysis.⁶

IV=intravenous; JAK=Janus kinase; SC=subcutaneous; S1P=Sphingosine-1-phosphate.

Endoscopic Control: Endoscopic Remission* Seen at Week 52 and up to ~3 Years^2,4,6

Prespecified Subgroup Analysis: In patients who responded to the FDA-approved 1200 mg IV induction dose

ENDOSCOPIC REMISSION UP TO ~3 YEARS^2,4,6
(Endoscopy subscore of 0)

Endoscopic remission rates in ulcerative colitis. At Week 52 in the COMMAND maintenance study, endoscopic remission was achieved by 26% of patients receiving SKYRIZI 180 mg SC, 35% receiving SKYRIZI 360 mg SC, and 16% receiving placebo. In the advanced therapy-naive subgroup, rates were 39%, 53%, and 20%, respectively. During the Week 152 open-label extension, endoscopic remission rates were 48% in the overall population and 59% in the advanced therapy-naive subgroup.

Continuous placebo data not intended for direct comparison.

ALL SUBJECTS MAINTENANCE POPULATION¹

In patients who responded to 1800 mg, 1200 mg or 600 mg in the Phase 2b/3 induction study; 600 mg and 1800 mg are not FDA-approved induction doses.

At Week 52, proportion of patients who achieved ENDOSCOPIC REMISSION* (secondary endpoint):

23%
SKYRIZI 180 mg SC
(n=179; P<0.05)

24%
SKYRIZI 360 mg SC
(n=186; P<0.05)

15%
Placebo (induction responders)^‡
(n=182)

LIMITATIONS: OLE: All patients completed the 52-week maintenance period and received SKYRIZI 180 mg Q8W regardless of the maintenance dose. An OLE may enrich long-term data as patients intolerant or unresponsive to the drug drop out. Endoscopies at Week 152 were locally read.
AO: A patient may not have had a response at each timepoint and any missing visit data were excluded from calculations for that visit, which may increase the percent responders. All observed data were used regardless of premature discontinuation of study drug or initiation of concomitant medication.³

LIMITATIONS OF PRESPECIFIED SUBGROUP ANALYSIS: Results shown are only among patients who responded to the FDA-approved 1200 mg IV induction dose. Excluded are those who received unapproved induction doses (600 mg or 1800 mg). Data were not controlled for multiplicity. No conclusions or statistical inferences can be made.²

All P-values are SKYRIZI treatment arms vs placebo (induction responders^‡).

^†Advanced therapy-naïve patients include some patients who were exposed to an advanced therapy (biologics, JAK inhibitors, and/or S1P receptor modulators) but did not experience treatment failure.¹

*Endoscopic improvement in UC is defined as Mayo endoscopic subscore of 0 or 1 without friability.¹ Endoscopic results are based on a full colonoscopy or flexible sigmoidoscopy, at the discretion of the investigator.⁵

^‡Patients who achieved clinical response with SKYRIZI induction therapy and were randomized to receive placebo in the maintenance study.⁵

^§Patients who responded to placebo in induction were not randomized and continued on placebo in maintenance. These patients were not included in the primary efficacy analysis.⁶

IV=intravenous; JAK=Janus kinase; SC=subcutaneous; S1P=Sphingosine-1-phosphate.

DURABLE REMISSION

Durable Remission at Week 52 and Data up to ~3 Years^2,3,6

Prespecified Subgroup Analysis: In patients who responded to the FDA-approved 1200 mg IV induction dose

CLINICAL REMISSION UP TO ~3 YEARS^2,3,6
(Composite of rectal bleeding, stool frequency, and endoscopy subscores)

Clinical remission rates in ulcerative colitis. At Week 12 in the INSPIRE induction study, clinical remission was achieved by 24% of patients receiving SKYRIZI 1200 mg IV versus 8% receiving placebo, and by 33% versus 9% in the advanced therapy-naive subgroup. At Week 52 in the COMMAND maintenance study, remission rates were 45% with SKYRIZI 180 mg SC, 41% with SKYRIZI 360 mg SC, and 26% with placebo.

Continuous placebo data not intended for direct comparison.

ALL SUBJECTS MAINTENANCE POPULATION¹

In patients who responded to 1800 mg, 1200 mg or 600 mg in the Phase 2b/3 induction study; 600 mg and 1800 mg are not FDA-approved induction doses.

At Week 52, proportion of patients who achieved CLINICAL REMISSION* (primary endpoint):

45%
SKYRIZI 180 mg SC
(n=179; P<0.001)

41%
SKYRIZI 360 mg SC
(n=186; P<0.001)

26%
Placebo (induction responders)^‡
(n=182)

LIMITATIONS: OLE: All patients completed the 52-week maintenance period and received SKYRIZI 180 mg Q8W regardless of the maintenance dose. An OLE may enrich long-term data as patients intolerant or unresponsive to the drug drop out. Endoscopies at Week 152 were locally read.
AO: A patient may not have had a response at each timepoint and any missing visit data were excluded from calculations for that visit, which may increase the percent responders. All observed data were used regardless of premature discontinuation of study drug or initiation of concomitant medication.³

LIMITATIONS OF PRESPECIFIED SUBGROUP ANALYSIS: Results shown are only among patients who responded to the FDA-approved 1200 mg IV induction dose. Excluded are those who received unapproved induction doses (600 mg or 1800 mg). Data were not controlled for multiplicity. No conclusions or statistical inferences can be made.²

All P-values are SKYRIZI treatment arms vs placebo.

In a post hoc analysis of patients who responded to the FDA-approved 1200 mg IV induction dose, among those in clinical remission at Week 52,
>97% were also corticosteroid-free for ≥90 days prior to visit.²

(180 mg [N=39/40]; 360 mg [N=44/45]; placebo [induction responders^‡] [N=26/26])

POST HOC LIMITATION: Data were not controlled for multiplicity. No conclusions or statistical inferences can be made.

In the overall population of the prespecified subgroup analysis, the corticosteroid-free clinical remission endpoint^|| was achieved at Week 52: 29% in placebo (induction responders^‡), 44% in SKYRIZI 180 mg, and 48% in SKYRIZI 360 mg.²

^†Advanced therapy-naïve patients include some patients who were exposed to an advanced therapy (biologics, JAK inhibitors, and/or S1P receptor modulators) but did not experience treatment failure.¹

*Clinical remission in UC is defined as stool frequency subscore ≤1 and not greater than baseline, rectal bleeding subscore of 0, and endoscopic subscore ≤1 without friability.¹

^‡Patients who achieved clinical response with SKYRIZI induction therapy and were randomized to receive placebo in the maintenance study.⁵

^§Patients who responded to placebo in induction were not randomized and continued on placebo in maintenance. These patients were not included in the primary efficacy analysis.⁶

^IISteroid-free clinical remission in UC is defined as clinical remission per modified Mayo Score (rectal bleeding, stool frequency, endoscopic subscore) at Week 52 and corticosteroid-free for ≥90 days immediately preceding Week 52.¹

IV=intravenous; JAK=Janus kinase; SC=subcutaneous; S1P=Sphingosine-1-phosphate.

Steroid-free Remission in UC at 1 Year^2,6

Prespecified Subgroup Analysis: In patients who responded to the FDA-approved 1200 mg IV induction dose

CORTICOSTEROID-FREE CLINICAL REMISSION* AT WEEK 52^2,6

Steroid-free clinical remission rates in ulcerative colitis. At Week 52 in the COMMAND maintenance study, steroid-free remission was achieved by 44% of patients receiving SKYRIZI 180 mg SC, 48% receiving SKYRIZI 360 mg SC, and 29% receiving placebo. In the advanced therapy-naive subgroup, rates were 59%, 66%, and 32%, respectively.

Continuous placebo data not intended for direct comparison.

ALL SUBJECTS MAINTENANCE POPULATION¹

In patients who responded to 1800 mg, 1200 mg or 600 mg in the Phase 2b/3 induction study; 600 mg and 1800 mg are not FDA-approved induction doses.

At Week 52, proportion of patients who achieved ENDOSCOPIC IMPROVEMENT* (secondary endpoint):

45%
SKYRIZI 180 mg SC
(n=179; P<0.001)

40%
SKYRIZI 360 mg SC
(n=186; P<0.001)

26%
Placebo (induction responders)^‡
(n=182)

Steroid-free for
≥90 DAYS prior to visit¹

LIMITATIONS OF PRESPECIFIED SUBGROUP ANALYSIS: Results shown are only among patients who responded to the FDA-approved 1200 mg IV induction dose. Excluded are those who received unapproved induction doses (600 mg or 1800 mg). Data were not controlled for multiplicity. No conclusions or statistical inferences can be made.²

All P-values are SKYRIZI treatment arms vs placebo.

^†Advanced therapy-naïve patients include some patients who were exposed to an advanced therapy (biologics, JAK inhibitors, and/or S1P receptor modulators) but did not experience treatment failure.¹

*Steroid-free clinical remission in UC is defined as clinical remission per modified Mayo Score (rectal bleeding, stool frequency, endoscopic subscore) at Week 52 and corticosteroid-free for ≥90 days immediately preceding Week 52.¹

^‡Patients who achieved clinical response with SKYRIZI induction therapy and were randomized to receive placebo in the maintenance study.⁵

^§Patients who responded to placebo in induction were not randomized and continued on placebo in maintenance. These patients were not included in the primary efficacy analysis.⁶

IV=intravenous; JAK=Janus kinase; SC=subcutaneous; S1P=Sphingosine-1-phosphate.

AFFIRM	SKYRIZI 720 mg SCN=180	Placebo N=94
Male, n (%)	103 (57.2)	53 (56.4)
Age (years), mean (SD)	40 (14.1)	38.6 (14.8)
Disease duration (years), mean (SD)	8.7 (9.0)	7.1 (8.0)
Disease location
Ileal only, n (%)	21 (11.7)	15 (16.0)
Colonic only, n (%)	58 (32.2)	30 (31.9)
Ileal-colonic, n (%)	101 (56.1)	49 (52.1)
hs-CRP (mg/L), median (min, max)	5.35 (0.2, 120.5)	5.15 (0.2, 129.4)
CDAI, mean (SD)	311.9 (54.3)	314.2 (55.5)
SES-CD, mean (SD)	13.3 (6.5)	12.7 (6.5)
Corticosteroid use, n (%)	43 (23.9)	25 (26.6)
*Advanced therapy failure history**
0, n (%)	65 (36.1)	33 (35.1)
1, n (%)	58 (32.2)	30 (31.9)
>1, n (%)	57 (31.7)	31 (33.0)

ADVANCE	SKYRIZI 600 mg IVN=336	Placebo N=175
Male, n (%)	189 (56)	88 (50)
Age (years), mean (SD)	38.3 (13.3)	37.1 (13.4)
Disease duration (years), mean (SD)	9.0 (8.8)	8.2 (7.1)
Disease location
Ileal only, n (%)	52 (15)	19 (11)
Colonic only, n (%)	115 (34)	70 (40)
Ileal-colonic, n (%)	169 (50)	86 (49)
hs-CRP (mg/L), median (IQR)	7.3 (2.8-21.8)	8.4 (2.8-21.9)
CDAI, mean (SD)	311.2 (62.4)	319.2 (59.4)
SES-CD, mean (SD)	14.7 (7.7)	13.8 (6.8)
Corticosteroid use, n (%)	102 (30)	50 (29)
*Advanced therapy failure history**
0, n (%)	141 (42)	78 (45)
1, n (%)	100 (30)	41 (23)
>1, n (%)	95 (28)	56 (32)

MOTIVATE	SKYRIZI 600 mg IVN=191	Placebo N=187
Male, n (%)	92 (48)	99 (53)
Age (years), mean (SD)	40.2 (13.6)	39.3 (13.5)
Disease duration (years), mean (SD)	10.9 (7.7)	12.5 (9.7)
Disease location
Ileal only, n (%)	33 (17)	26 (14)
Colonic only, n (%)	75 (39)	73 (39)
Ileal-colonic, n (%)	83 (43)	88 (47)
hs-CRP (mg/L), median (IQR)	9.3 (3.5-23.0)	9.4 (3.6-28.2)
CDAI, mean (SD)	310.7 (63.6)	319.6 (69.8)
SES-CD, mean (SD)	14.4 (7.6)	15.0 (8.1)
Corticosteroid use, n (%)	65 (34)	68 (36)
*Advanced therapy failure history**
0, n (%)	0	0
1, n (%)	92 (48)	88 (47)
>1, n (%)	99 (52)	99 (53)

FORTIFY	SKYRIZI 180 mg SC N=135	SKYRIZI 360 mg SC N=117	Placebo (Induction Responders^†)N=130
Baseline of Induction (ADVANCE, MOTIVATE)
Male, n (%)	62 (45.9)	67 (57.3)	72 (55.4)
Age (years), mean (SD)	39.2 (14.7)	36.2 (12.6)	38.0 (12.8)
Disease duration (years), mean (SD)	10.6 (10.2)	8.6 (7.1)	9.6 (8.2)
Disease location
Ileal only, n (%)	12 (9)	13 (11)	18 (14)
Colonic only, n (%)	63 (47)	52 (44)	49 (38)
Ileal-colonic, n (%)	60 (44)	52 (44)	63 (49)
Baseline immunomodulator use, n (%)	37 (27.4)	34 (29.1)	33 (25.4)
Baseline steroid use, n (%)	47 (34.8)	36 (30.8)	40 (30.8)
*Advanced therapy failure history**
0, n (%)	40 (29.6)	34 (29.1)	31 (23.8)
1, n (%)	34 (25.2)	42 (35.9)	49 (37.7)
>1, n (%)	61 (45.2)	41 (35.0)	50 (38.5)
Baseline CDAI, mean (SD)	327.6 (68.2)	316.2 (59.6)	314.2 (64.2)
Baseline SES-CD, mean (SD)	14.9 (7.2)	14.3 (7.0)	14.1 (7.1)
Baseline SF, mean (SD)	6.2 (3.1)	5.9 (2.7)	5.8 (2.7)
Baseline APS, mean (SD)	2.0 (0.4)	1.9 (0.5)	1.9 (0.5)
Baseline FCP (mg/kg), median (min, max)	1666.0 (30, 28800)	1622.0 (30, 14649)	904.0 (30, 11378)
Baseline hs-CRP (mg/L), median (min, max)	8.7 (0.4, 151)	10.6 (0.3, 129)	7.9 (0.3, 181)
Week 0 of Maintenance
CDAI at Week 0, mean (SD)	117.6 (66.8)	125.4 (62.7)	111.6 (69.5)
SES-CD at Week 0, mean (SD)	7.8 (6.4)	8.3 (7.3)	7.3 (6.4)
SF at Week 0, mean (SD)	2.1 (1.9)	1.9 (1.7)	1.4 (1.7)
APS at Week 0, mean (SD)	0.6 (0.5)	0.6 (0.5)	0.6 (0.5)
FCP (mg/kg) at Week 0, median (min, max)	361 (30, 28800)	485.5 (30, 14804)	300.0 (30, 22912)
hs-CRP (mg/L) at Week 0, median (min, max)	3.7 (0, 48)	4.0 (0, 258)	3.6 (0, 42)

Baseline Characteristics	SKYRIZI 1200 mg IV N=646	PlaceboN=320
Female, %	41	38
Race (white), %	71	67
Median age, years	40	42
Median disease duration, years	6	6
Median weight, kg	70	71
Disease Extent
Left sided, %	48	46
Extensive/pancolitis, %	51	53
Median fecal calprotectin, mg/kg	1530 (n=598)	1624 (n=298)
Median hs-CRP, mg/L	3.4 (n=634)	4.0 (n=313)
Baseline immunosuppressant use, %	17	16
Baseline aminosalicylates use, %	73	73
Baseline corticosteroid use, %	36	35
Baseline Advanced Therapy Experience
Advanced therapy naïve,^a %	49	48
Advanced therapy failure,^b %	51	53
1	24	25
2	17	17
3+	11	11
Prior TNF use, %	86	84
Prior vedolizumab use, %	54	52
Prior JAK use, %	16	22
Baseline Modified Mayo Score
≤7, %	63	63
>7, %	38	37
Mean Mayo Endoscopy Subscore	2.7	2.7

EFFICACY DATA
FOR ULCERATIVE
COLITIS

Jump to:

Proven to Give Patients a Chance at Early Symptom Relief and Endoscopic Control¹

Patients Achieved Durable Remission at Weeks 12 and 52¹

Relief of Rectal Bleeding and Stool Frequency as Early as Week 4^1,2

Endoscopic Control: Endoscopic Improvement* Seen at Week 52 and up to ~3 Years^2,3,6

Endoscopic Control: Endoscopic Remission* Seen at Week 52 and up to ~3 Years^2,4,6

Durable Remission at Week 52 and Data up to ~3 Years^2,3,6

Steroid-free Remission in UC at 1 Year^2,6

Recommended for You

Open-Label Extension (OLE) Study Design

Key Baseline Characteristics Across the Study Populations^2,4-6

Open-Label Extension (OLE) Study Design

Open-Label Extension (OLE) Study Design

Key Baseline Characteristics Across the Study Populations^2,4-6

Open-Label Extension (OLE) Study Design

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

EFFICACY DATA FOR ULCERATIVE COLITIS

Jump to:

Proven to Give Patients a Chance at Early Symptom Relief and Endoscopic Control1

Patients Achieved Durable Remission at Weeks 12 and 521

Relief of Rectal Bleeding and Stool Frequency as Early as Week 41,2

Endoscopic Control: Endoscopic Improvement* Seen at Week 52 and up to ~3 Years2,3,6

Endoscopic Control: Endoscopic Remission* Seen at Week 52 and up to ~3 Years2,4,6

Durable Remission at Week 52 and Data up to ~3 Years2,3,6

Steroid-free Remission in UC at 1 Year2,6

Recommended for You

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

EFFICACY DATA
FOR ULCERATIVE
COLITIS

Proven to Give Patients a Chance at Early Symptom Relief and Endoscopic Control¹

Patients Achieved Durable Remission at Weeks 12 and 52¹

Relief of Rectal Bleeding and Stool Frequency as Early as Week 4^1,2

Endoscopic Control: Endoscopic Improvement* Seen at Week 52 and up to ~3 Years^2,3,6

Endoscopic Control: Endoscopic Remission* Seen at Week 52 and up to ~3 Years^2,4,6

Durable Remission at Week 52 and Data up to ~3 Years^2,3,6

Steroid-free Remission in UC at 1 Year^2,6

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹